Library — CHDR

Search

Filter

Measuring blood-brain barrier penetration using the NeuroCart, a CNS test battery.

Groeneveld GJ, Hay JL, Van Gerven JM

Drug discovery today. Technologies, 2016 Jun

View publication
Biomarkers for the effects of antipsychotic drugs in healthy volunteers.

de Visser SJ, van der Post J, Pieters MS, Cohen AF, van Gerven JM

British journal of clinical pharmacology, 2001 Jan; 51(2):119-32

View publication
Effects of temazepam on saccadic eye movements: concentration-effect relationships in individual volunteers.

van Steveninck AL, Verver S, Schoemaker HC, Pieters MS, Kroon R, Breimer DD, Cohen AF

Clinical pharmacology and therapeutics, 1992 Sep; 52(4):402-8

View publication
Integrated pharmacokinetics and pharmacodynamics of Ro 48-6791, a new benzodiazepine, in comparison with midazolam during first administration to healthy male subjects.

Dingemanse J, van Gerven JM, Schoemaker RC, Roncari G, Oberyé JJ, van Oostenbruggen MF, Massarella J, Segala P, Zell M, Cohen AF

British journal of clinical pharmacology, 1997 Oct; 44(5):477-86

View publication
Central nervous system effects of moxonidine experimental sustained release formulation in patients with mild to moderate essential hypertension.

Kemme MJ, vd Post JP, Schoemaker RC, Straub M, Cohen AF, van Gerven JM

British journal of clinical pharmacology, 2003 May; 55(6):518-25

View publication
Biomarkers for the effects of cannabis and THC in healthy volunteers.

Zuurman L, Ippel AE, Moin E, van Gerven JM

British journal of clinical pharmacology, 2008 Dec; 67(1):5-21

View publication
Orexin receptor antagonism: an ascending multiple-dose study with almorexant.

Hoever P, de Haas SL, Dorffner G, Chiossi E, van Gerven JM, Dingemanse J

Journal of psychopharmacology (Oxford, England), 2012 Jul; 26(8):1071-80

View publication
Early stage development of the glycine-1 re-uptake inhibitor SCH 900435: central nervous system effects compared with placebo in healthy men.

Liem-Moolenaar M, Peeters P, Kamerling IM, Hogg C, Holder G, Kleijn HJ, Spaans E, Udo De Haes J, de Kam ML, Franson KL, Cohen AF, van Gerven JM

British journal of clinical pharmacology, 2013 May; 75(6):1455-67

View publication
Pharmacokinetic and pharmacodynamic interactions between almorexant, a dual orexin receptor antagonist, and desipramine.

Cruz HG, Hay JL, Hoever P, Alessi F, te Beek ET, van Gerven JM, Dingemanse J

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2014 Jul; 24(8):1257-68

View publication

«
1
2
3
4
5
6
7
8
9
10
»